Physician profile
Angelika Ludtke Erwin
NPI 1417117243
$224,582.14
in general payments reported to CMS, 2019-2025
11 companies · $15K in 2025
The $15K reported for 2025 was more than what 89% of Clinical Genetics (M.D.) providers received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $18K · 2021: $21K · 2022: $58K · 2023: $70K · 2024: $23K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $89K · Consulting Fee: $16K · Travel and Lodging: $2,633 · Food and Beverage: $1,602 · Honoraria: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $88,524.25 |
| Consulting Fee | $15,819.00 |
| Travel and Lodging | $2,633.08 |
| Food and Beverage | $1,601.85 |
| Honoraria | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $132,939.86 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $65,149.33 | 2019-2025 | Givlaari |
| Sanofi-Aventis U.S. LLC | $11,769.67 | 2021-2023 | |
| Recordati_rare_diseases_inc. | $4,500.00 | 2022 | |
| Mitsubishi Tanabe Pharma Development America, INC. | $2,760.00 | 2022 | |
| Tanabe Pharma America, INC. | $2,760.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,400.00 | 2020 | |
| Chiesi USA, INC. | $2,240.00 | 2023-2025 | Elfabrio |
| Biomarin Pharmaceutical INC. | $49.89 | 2020 | |
| Travere Therapeutics, INC. | $13.39 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angelika Erwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.